scispace - formally typeset
Journal ArticleDOI

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

TLDR
In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.
Abstract
Background Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 ...

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

miRNAs: micro-managers of anticancer combination therapies

TL;DR: The provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer are reviewed.
Journal ArticleDOI

Reassessment of the role of induction chemotherapy for head and neck cancer

TL;DR: Data is summarized for the use of induction chemotherapy in the setting of locally advanced disease--both resectable and unresectable and which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials.
Journal ArticleDOI

Head and Neck: Squamous cell carcinoma: an overview

TL;DR: Review on Head and Neck: Squamous cell carcinoma: an overview, with data on clinics, and the genes involved.
Journal ArticleDOI

Emerging insights into head and neck cancer metastasis

TL;DR: The role of regional lymph nodes in containing advanced head and neck cancer, evidence for active as opposed to passive tumor cell metastasis, and clinical implications these concepts have on both treatment of head andneck cancer and future research are reviewed.
Journal ArticleDOI

Supraclavicular flap reconstruction following total laryngectomy.

TL;DR: Report on the successful use of the supraclavicular flap for reconstruction following total laryngectomy and highlight the utility and versatility of this flap.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

TL;DR: In this article, a multiple comparison procedure for comparing several treatments with a control is presented, which is based on the Multiple Comparison Procedure for Comparing Several Treatments with a Control (MCPC).
Journal ArticleDOI

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

Robert Gray
- 01 Jan 1988 - 
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI

Cancer statistics, 2003.

TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year, and compiles the most recent data on cancer incidence, mortality, and survival by using incidence data from the National Cancer Institute (NCI) and mortality data from National Center for Health Statistics (NCHS).
Related Papers (5)